



CGT Therapies for everyone!

02 – 03 January 2026 | **SaxoCell Conference**, Dresden, Germany
Speaker: Dr.-Ing. Patrick Bongartz, CEO & Founder





Who we are

Our Company



Our Key Facts

- Founded in 2022
- Pre-seed round raised in Q1 2024
- Won EIC Accelerator €10 million blended package in Q1 2025
- Secured German grants for CGT scale-up in 2025 totaling >€2.5 million

- Located in Aachen, Germany
- Almost 30 employees across business, biology, engineering and manufacturing
- Direct exports & support to EMEA & NA
- Cooperation with **REPROCELL** for global ComfyCell Incu distribution



Our Mission

Make novel therapies available to everyone by providing the best possible bioreactor system for scalable and intensified bioprocessing!

Our Offering



ComfyCell Benchtop



ComfyCell Incu



Process development

Our Business Areas




By application

- iPSCs
- Carriers
- Spheroids
- Encapsulated
- MSCs
- Organoids
- Cardiomyocytes
- Lung
- Other
- NK
- iNK
- NK-92
- Primary NK
- T-Cells
- CAR-T
- EVs
- Viral Vectors
- CHO Cells
- HEK293
- Insect Cells
- Cultured Meat
- Cell-free Systems

● = data or reference available
● = in progress



By region





Who we are

Our Core Team



Co-Founder
Dr.-Ing. Patrick Bongartz
CEO



Co-Founder
Moritz Meyer
CTO



Co-Founder
Konstantin Kurz
CFO



Dr. Yasemin van Heuvel
Sr. Bioprocess Expert



Dr. Marco Oliveira
Sr. Bioprocess Expert



Felipe Véliz Valenzuela
Bioprocess Expert



Paul Fliser
Head of Sales



Jesse Harenkamp
Founders Associate



Florian Huber
Product Developer



Lukas Keischgens
Product Developer



Jannis Focke
Product Developer



Johannes Wolski
Electrical Engineer

Advisors



Prof. Dr. Matthias Wessling
Scientific Advisor
RWTH AACHEN UNIVERSITY



Fabien Moncaubeig
Strategic Advisor
TreeFrog therapeutics



Reinout Hesselink, PhD
Regulatory Advisor
Maastricht University

Investors



The CGT market is expanding...

>1 billion
...addressable patients with
CGTs in pipeline^{1,3}

1st

...iPSC-derived therapy approved in January
2026, with growing number of therapies to
follow

47%

...of global biologics pipeline drugs will
be CGT³, showing a CAGR of 20%²



Diabetes

Pioneered by:

VERTEX

Sana
Biotechnology



Parkinson

Pioneered by:

BAYER

BlueRock

Sumitomo Pharma


TreeFrog
therapeutics



Heart Failure

Pioneered by:

CUORIPS



Cancer

Pioneered by:

Kite
A GILEAD Company

NOVARTIS

Bristol Myers Squibb™



...but lacking a clear path to cost effective cell manufacturing

Stacked petri-dishes or scale out processes [2D]



Max
Scale:
2 L



Costly



Inferior quality compared to 3D cultivation



Inconsistent monitoring = **high batch-to-batch variability**

Conventional bioreactors [3D]



Max
Scale:
10 L¹



Still costly



Bubble-aeration = high shear



No scale up > 10 L

Us € Membrane stirrer



Max
Scale:
1000 L



No foam & gentle mixing—reduced shear!




Hollow-fiber technology = 10x better mass transfer




Truly scalable – minimizing costs!

Our solution - the Membrane Stirrer


Diffusive gas transfer - **bubble** & foam-free aeration



Rotor-like membrane - **optimal mixing** at low RPM




Up to 10x higher gas transfer






In Development:

In-situ cell
retention filter for
continuous media
exchange.



Our applications

Overview: Available data and running projects



= Excellent results



= POC available




= In progress



= Available under NDA

With SAHOCCELL® - 10 Batches to 1: Scaling for Efficiency



1: Assumed quantity of cells for clinical trial of size n = 50, dose size of 5×10^9 NK cells

Thank you for your kind attention.

We are happy to chat!



Dr.-Ing. Patrick Bongartz
patrick.bongartz@biothrust.de
+49 15783041211
www.biothrust.de



Dr. Yasemin van Heuvel
yasemin.vanheuvel@biothrust.de
+49 15783041178
www.biothrust.de



BIOTHRUST

Our ComfyCell unlocks up to 10X cost reduction for CGT therapies, becoming the enabler for the new biopharma era

